In nude mice bearing NSCLC H3122 CDX tumors with EML4-ALK fusion, APG-2449 25, 50, or 100 mg/kg exerted dose-dependent antitumor activity, with T/C (%) values of 57.8% (1/7 stable disease [mSD], 6/7 progressive disease [mPD]), 17.5% [1/7 partial response [mPR], 6/7 mSD), and 5% (1/7 complete response [mCR], 6/7 mPR), respectively (Fig. 2A). Here, EML4 is linked to non-small cell lung carcinoma.